PSS14 REAL-WORLD COSTS IN BIOLOGIC-NAIVE PSORIASIS PATIENTS INITIATING APREMILAST OR BIOLOGICS IN A US HEALTHCARE CLAIMS DATABASE.

In all, 1,645 biologic-naive psoriasis patients initiating apremilast were matched to 1,645 biologic-naive psoriasis patients initiating biologics (TNF: n=1,207; IL: n=438). Biologic-naive psoriasis patients initiating apremilast had significantly lower healthcare costs than patients initiating TNF and IL inhibitors. [Extracted from the article]